Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) StudyYoav H. Messinger, Bruce Bostrom, Paul S. Gaynon et al.|Blood|2012Cited by 205
Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): A report from the therapeutic advances in childhood leukemia (TACL) consortiumYoav H. Messinger, Bruce Bostrom, Elizabeth A. Raetz et al.|Pediatric Blood & Cancer|2010Cited by 114
Bortezomib Combined with VXLD Chemotherapy Is Highly Effective In Advanced B-Lineage Acute Lymphoblastic Leukemia Allowing Early Study Termination Due to Efficacy. A Therapeutic Advances in Childhood Leukemia (TACL) Consortium Phase II StudyYoav H. Messinger, Bruce Bostrom, Paul S. Gaynon et al.|Blood|2011Cited by 11
Remarkable Activity of Bortezomib Combined with Chemotherapy in a Phase I Study of Relapsed Childhood Acute Lymphoblastic Leukemia (ALL). A Report from the Therapeutic Advances in Childhood Leukemia (TACL) Consortium.Yoav H. Messinger, Bruce Bostrom, Elena Eckroth et al.|Blood|2008Cited by 5